Eculizumab biosimilar - AmgenAlternative Names: ABP 959
Latest Information Update: 17 Feb 2017
At a glance
- Originator Amgen
- Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies
- Mechanism of Action Complement C5 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 15 Mar 2016 Biomarkers information updated